kth.sePublications
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 42) Show all publications
Johansson, C., Hunt, H., Signorelli, M., Edfors, F., Hober, A., Svensson, A.-S., . . . Al-Khalili Szigyarto, C. (2023). Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers. Clinical Proteomics, 20(1), Article ID 23.
Open this publication in new window or tab >>Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
Show others...
2023 (English)In: Clinical Proteomics, ISSN 1542-6416, E-ISSN 1559-0275, Vol. 20, no 1, article id 23Article in journal (Refereed) Published
Abstract [en]

Background

Molecular components in blood, such as proteins, are used as biomarkers to detect or predict disease states, guide clinical interventions and aid in the development of therapies. While multiplexing proteomics methods promote discovery of such biomarkers, their translation to clinical use is difficult due to the lack of substantial evidence regarding their reliability as quantifiable indicators of disease state or outcome. To overcome this challenge, a novel orthogonal strategy was developed and used to assess the reliability of biomarkers and analytically corroborate already identified serum biomarkers for Duchenne muscular dystrophy (DMD). DMD is a monogenic incurable disease characterized by progressive muscle damage that currently lacks reliable and specific disease monitoring tools.

Methods

Two technological platforms are used to detect and quantify the biomarkers in 72 longitudinally collected serum samples from DMD patients at 3 to 5 timepoints. Quantification of the biomarkers is achieved by detection of the same biomarker fragment either through interaction with validated antibodies in immuno-assays or through quantification of peptides by Parallel Reaction Monitoring Mass Spectrometry assay (PRM-MS).

Results

Five, out of ten biomarkers previously identified by affinity-based proteomics methods, were confirmed to be associated with DMD using the mass spectrometry-based method. Two biomarkers, carbonic anhydrase III and lactate dehydrogenase B, were quantified with two independent methods, sandwich immunoassays and PRM-MS, with Pearson correlations of 0.92 and 0.946 respectively. The median concentrations of CA3 and LDHB in DMD patients was elevated in comparison to those in healthy individuals by 35- and 3-fold, respectively. Levels of CA3 vary between 10.26 and 0.36 ng/ml in DMD patients whereas those of LDHB vary between 15.1 and 0.8 ng/ml.

Conclusions

These results demonstrate that orthogonal assays can be used to assess the analytical reliability of biomarker quantification assays, providing a means to facilitate the translation of biomarkers to clinical practice. This strategy also warrants the development of the most relevant biomarkers, markers that can be reliably quantified with different proteomics methods.

Place, publisher, year, edition, pages
Springer Nature, 2023
Keywords
Duchenne muscular dystrophy, Serum biomarkers, Biomarker quantification, Sandwich immunoassay, Mass spectrometry, Parallel reaction monitoring
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:kth:diva-330521 (URN)10.1186/s12014-023-09412-1 (DOI)001004960700001 ()37308827 (PubMedID)2-s2.0-85161893058 (Scopus ID)
Note

QC 20231023

Available from: 2023-06-30 Created: 2023-06-30 Last updated: 2023-12-07Bibliographically approved
Hober, A., Rekanovic, M., Forsström, B., Hansson, S., Kotol, D., Percy, A. J., . . . Miliotis, T. (2023). Targeted proteomics using stable isotope labeled protein fragments enables precise and robust determination of total apolipoprotein(a) in human plasma. PLOS ONE, 18(2 February), Article ID e0281772.
Open this publication in new window or tab >>Targeted proteomics using stable isotope labeled protein fragments enables precise and robust determination of total apolipoprotein(a) in human plasma
Show others...
2023 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 18, no 2 February, article id e0281772Article in journal (Refereed) Published
Abstract [en]

Lipoprotein(a), also known as Lp(a), is an LDL-like particle composed of apolipoprotein(a) (apo(a)) bound covalently to apolipoprotein B100. Plasma concentrations of Lp(a) are highly heritable and vary widely between individuals. Elevated plasma concentration of Lp(a) is considered as an independent, causal risk factor of cardiovascular disease (CVD). Targeted mass spectrometry (LC-SRM/MS) combined with stable isotope-labeled recombinant proteins provides robust and precise quantification of proteins in the blood, making LC-SRM/ MS assays appealing for monitoring plasma proteins for clinical implications. This study presents a novel quantitative approach, based on proteotypic peptides, to determine the absolute concentration of apo(a) from two microliters of plasma and qualified according to guideline requirements for targeted proteomics assays. After optimization, assay parameters such as linearity, lower limits of quantification (LLOQ), intra-assay variability (CV: 4.7%) and inter-assay repeatability (CV: 7.8%) were determined and the LC-SRM/MS results were benchmarked against a commercially available immunoassay. In summary, the measurements of an apo(a) single copy specific peptide and a kringle 4 specific peptide allow for the determination of molar concentration and relative size of apo(a) in individuals.

Place, publisher, year, edition, pages
Public Library of Science (PLoS), 2023
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:kth:diva-330004 (URN)10.1371/journal.pone.0281772 (DOI)001056479600060 ()36791076 (PubMedID)2-s2.0-85148250236 (Scopus ID)
Note

QC 20230629

Available from: 2023-06-29 Created: 2023-06-29 Last updated: 2023-12-07Bibliographically approved
Mikus, M., Zandian, A., Sjöberg, R., Hamsten, C., Forsström, B., Andersson, M., . . . Ohlin, M. (2021). Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 147(3), 1077-1086
Open this publication in new window or tab >>Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy
Show others...
2021 (English)In: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 147, no 3, p. 1077-1086Article in journal (Refereed) Published
Abstract [en]

Background: The interaction of allergens and allergen-specific IgE initiates the allergic cascade after crosslinking of receptors on effector cells. Antibodies of other isotypes may modulate such a reaction. Receptor crosslinking requires binding of antibodies to multiple epitopes on the allergen. Limited information is available on the complexity of the epitope structure of most allergens. Objectives: We sought to allow description of the complexity of IgE, IgG4, and IgG epitope recognition at a global, allergome-wide level during allergen-specific immunotherapy (AIT). Methods: We generated an allergome-wide microarray comprising 731 allergens in the form of more than 172,000 overlapping 16-mer peptides. Allergen recognition by IgE, IgG4, and IgG was examined in serum samples collected from subjects undergoing AIT against pollen allergy. Results: Extensive induction of linear peptide-specific Phl p 1– and Bet v 1–specific humoral immunity was demonstrated in subjects undergoing a 3-year-long AIT against grass and birch pollen allergy, respectively. Epitope profiles differed between subjects but were largely established already after 1 year of AIT, suggesting that dominant allergen-specific antibody clones remained as important contributors to humoral immunity following their initial establishment during the early phase of AIT. Complex, subject-specific patterns of allergen isoform and group cross-reactivities in the repertoires were observed, patterns that may indicate different levels of protection against different allergen sources. Conclusions: The study highlights the complexity and subject-specific nature of allergen epitopes recognized following AIT. We envisage that epitope deconvolution will be an important aspect of future efforts to describe and analyze the outcomes of AIT in a personalized manner.

Place, publisher, year, edition, pages
Elsevier BV, 2021
Keywords
Allergen, IgE, IgG, IgG4, allergen-specific immunotherapy, antibody, epitope, linear epitope, peptide microarray
National Category
Organic Chemistry
Identifiers
urn:nbn:se:kth:diva-284984 (URN)10.1016/j.jaci.2020.08.002 (DOI)000635524300012 ()32791163 (PubMedID)2-s2.0-85091214366 (Scopus ID)
Note

QC 20250318

Available from: 2020-12-22 Created: 2020-12-22 Last updated: 2025-03-18Bibliographically approved
Li, X., Kim, W., Arif, M., Gao, C., Hober, A., Kotol, D., . . . Mardinoglu, A. (2021). Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers. Cancers, 13(2), Article ID 348.
Open this publication in new window or tab >>Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers
Show others...
2021 (English)In: Cancers, ISSN 2072-6694, Vol. 13, no 2, article id 348Article in journal (Refereed) Published
Abstract [en]

Simple Summary Pyruvate kinase muscle type (PKM) is a key enzyme in glycolysis and is a mediator of the Warburg effect in tumors. The association of PKM with survival of cancer patients is controversial. In this study, we investigated the associations of the alternatively spliced transcripts of PKM with cancer patients' survival outcomes and explained the conflicts in previous studies. We discovered three poorly studied alternatively spliced PKM transcripts that exhibited opposite prognostic indications in different human cancers based on integrative systems analysis. We also detected their protein products and explored their potential biological functions based on in-vitro experiments. Our analysis demonstrated that alternatively spliced transcripts of not only PKM but also other genes should be considered in cancer studies, since it may enable the discovery and targeting of the right protein product for development of the efficient treatment strategies. Pyruvate kinase muscle type (PKM) is a key enzyme in glycolysis and plays an important oncological role in cancer. However, the association of PKM expression and the survival outcome of patients with different cancers is controversial. We employed systems biology methods to reveal prognostic value and potential biological functions of PKM transcripts in different human cancers. Protein products of transcripts were shown and detected by western blot and mass spectrometry analysis. We focused on different transcripts of PKM and investigated the associations between their mRNA expression and the clinical survival of the patients in 25 different cancers. We find that the transcripts encoding PKM2 and three previously unstudied transcripts, namely ENST00000389093, ENST00000568883, and ENST00000561609, exhibited opposite prognostic indications in different cancers. Moreover, we validated the prognostic effect of these transcripts in an independent kidney cancer cohort. Finally, we revealed that ENST00000389093 and ENST00000568883 possess pyruvate kinase enzymatic activity and may have functional roles in metabolism, cell invasion, and hypoxia response in cancer cells. Our study provided a potential explanation to the controversial prognostic indication of PKM, and could invoke future studies focusing on revealing the biological and oncological roles of these alternative spliced variants of PKM.

Place, publisher, year, edition, pages
MDPI AG, 2021
Keywords
alternative splicing, cancer, PKM, transcriptomics
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:kth:diva-289916 (URN)10.3390/cancers13020348 (DOI)000611155000001 ()33478099 (PubMedID)2-s2.0-85100137584 (Scopus ID)
Note

QC 20210211

Available from: 2021-02-11 Created: 2021-02-11 Last updated: 2023-12-07Bibliographically approved
Jahn, M., Crang, N., Janasch, M., Hober, A., Forsström, B., Kimler, K., . . . Hudson, E. P. (2021). Protein allocation and utilization in the versatile chemolithoautotroph Cupriavidus necator. eLIFE, 10, Article ID e69019.
Open this publication in new window or tab >>Protein allocation and utilization in the versatile chemolithoautotroph Cupriavidus necator
Show others...
2021 (English)In: eLIFE, E-ISSN 2050-084X, Vol. 10, article id e69019Article in journal (Refereed) Published
Abstract [en]

Bacteria must balance the different needs for substrate assimilation, growth functions, and resilience in order to thrive in their environment. Of all cellular macromolecules, the bacterial proteome is by far the most important resource and its size is limited. Here, we investigated how the highly versatile 'knallgas' bacterium Cupriavidus necator reallocates protein resources when grown on different limiting substrates and with different growth rates. We determined protein quantity by mass spectrometry and estimated enzyme utilization by resource balance analysis modeling. We found that C. necator invests a large fraction of its proteome in functions that are hardly utilized. Of the enzymes that are utilized, many are present in excess abundance. One prominent example is the strong expression of CBB cycle genes such as Rubisco during growth on fructose. Modeling and mutant competition experiments suggest that CO2-reassimilation through Rubisco does not provide a fitness benefit for heterotrophic growth, but is rather an investment in readiness for autotrophy.

Place, publisher, year, edition, pages
eLIFE SCIENCES PUBL LTD, 2021
Keywords
Cupriavidus necator, Ralstonia eutropha, resource balance analysis, substrate limitation, co2 fixation, gene fitness, Other
National Category
Biochemistry Molecular Biology
Identifiers
urn:nbn:se:kth:diva-307024 (URN)10.7554/eLife.69019 (DOI)000730627000001 ()34723797 (PubMedID)2-s2.0-85120872983 (Scopus ID)
Note

See also peer review documents at DOI 10.7554/eLife.69019.sa0  10.7554/eLife.69019.sa1  10.7554/eLife.69019.sa2

QC 20220111

Available from: 2022-01-11 Created: 2022-01-11 Last updated: 2025-02-20Bibliographically approved
Sahlstrom, P., Hansson, M., Steen, J., Amara, K., Titcombe, P. J., Forsström, B., . . . Gronwall, C. (2020). Different Hierarchies of Anti-Modified Protein Autoantibody Reactivities in Rheumatoid Arthritis. Arthritis & Rheumatology, 72(10), 1643-1657
Open this publication in new window or tab >>Different Hierarchies of Anti-Modified Protein Autoantibody Reactivities in Rheumatoid Arthritis
Show others...
2020 (English)In: Arthritis & Rheumatology, ISSN 2326-5191, E-ISSN 2326-5205, Vol. 72, no 10, p. 1643-1657Article in journal (Refereed) Published
Abstract [en]

Objective. Anti-citrullinated protein antibodies (ACPAs) are a hallmark of seropositive rheumatoid arthritis (RA). Yet, the precise disease-relevant autoantigens that are targeted by ACPAs remains a matter of debate. This study utilized patient-derived monoclonal ACPAs, rather than serum autoantibody analysis, to characterize the multireactivity to different protein modifications and to reveal autoantibody subsets in patients with RA. Methods. Twelve human monoclonal ACPAs (positive by the second-generation cyclic citrullinated peptide test) were generated from 6 RA patients, and a head-to-head comparison of their reactivities was performed. For profiling, we used a complementary DNA-based protein array (Engine GmbH) and 3 peptide-screening platforms with RA autoantigens (Thermo Fisher Scientific), citrullinated and carbamylated peptides (NimbleGen/Roche), or histonederived peptides with different posttranslational modifications (JPT Histone Code), covering >207,000 peptides (>7,800 gene products). Results. The fine-specificity profiles of the investigated ACPAs varied, but all of the monoclonal ACPAs displayed multireactivity to a large number of citrullinated peptides/proteins, each characterized by specific binding properties. ACPA subsets could be defined by clone-distinct consensus binding motifs (e.g., Cit-Gly, Gly-Cit, or Arg-Cit-Asp), with the most common ACPA recognition being that of a Gly in the +1 flanking position, but with additional amino acid preferences. For ACPA protein recognition, we observed a preference for citrullinated RNA-binding proteins with high Arg/Gly content. Six of the 12 ACPA clones also bound acetylated-lysine (KAc) or homocitrulline peptide motifs, displaying a similar affinity or higher apparent affinity than that for Cit peptides. Conclusion. ACPAs and anti-modified protein autoantibodies represent overlapping facets of RA autoimmunity and bind to a wide variety of modified proteins, extending well beyond the historically recognized set of RA autoantigens. So far, KAc reactivity has been detected only in the context of anti-Carb and anti-Cit peptide autoantibody responses, postulating the existence of hierarchies of autoreactivity in RA. Future investigations of ACPA fine specificities and functionality should take into consideration the presence of consensus Cit/Carb/KAc motifs and the multireactivity of these autoantibodies in patients with RA.

Place, publisher, year, edition, pages
WILEY, 2020
National Category
Clinical Medicine
Identifiers
urn:nbn:se:kth:diva-283895 (URN)10.1002/art.41385 (DOI)000572662600007 ()32501655 (PubMedID)2-s2.0-85090449449 (Scopus ID)
Note

QC 20201201

Available from: 2020-12-01 Created: 2020-12-01 Last updated: 2025-02-18Bibliographically approved
Dodig-Crnkovic, T., Hong, M.-G., Thomas, C. E., Häussler, R. S., Bendes, A., Dale, M., . . . Schwenk, J. M. (2020). Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling. EBioMedicine, 57, Article ID 102854.
Open this publication in new window or tab >>Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling
Show others...
2020 (English)In: EBioMedicine, E-ISSN 2352-3964, Vol. 57, article id 102854Article in journal (Refereed) Published
Abstract [en]

Background: Precision medicine approaches aim to tackle diseases on an individual level through molecular profiling. Despite the growing knowledge about diseases and the reported diversity of molecular phenotypes, the descriptions of human health on an individual level have been far less elaborate. Methods: To provide insights into the longitudinal protein signatures of well-being, we profiled blood plasma collected over one year from 101 clinically healthy individuals using multiplexed antibody assays. After applying an antibody validation scheme, we utilized > 700 protein profiles for in-depth analyses of the individuals’ short-term health trajectories. Findings: We found signatures of circulating proteomes to be highly individual-specific. Considering technical and longitudinal variability, we observed that 49% of the protein profiles were stable over one year. We also identified eight networks of proteins in which 11–242 proteins covaried over time. For each participant, there were unique protein profiles of which some could be explained by associations to genetic variants. Interpretation: This observational and non-interventional study identifyed noticeable diversity among clinically healthy subjects, and facets of individual-specific signatures emerged by monitoring the variability of the circulating proteomes over time. To enable more personal hence precise assessments of health states, longitudinal profiling of circulating proteomes can provide a valuable component for precision medicine approaches. Funding: This work was supported by the Erling Persson Foundation, the Swedish Heart and Lung Foundation, the Knut and Alice Wallenberg Foundation, Science for Life Laboratory, and the Swedish Research Council.

Place, publisher, year, edition, pages
Elsevier, 2020
Keywords
Affinity proteomics, Longitudinal profiling, Plasma proteomics, pQTLs, Precision medicine
National Category
Medical Biotechnology
Identifiers
urn:nbn:se:kth:diva-279339 (URN)10.1016/j.ebiom.2020.102854 (DOI)000552273800011 ()32629387 (PubMedID)2-s2.0-85087302422 (Scopus ID)
Note

QC 20200824

Available from: 2020-08-20 Created: 2020-08-20 Last updated: 2024-03-15Bibliographically approved
Tegel, H., Dannemeyer, M., Kanje, S., Sivertsson, Å., Berling, A., Svensson, A.-S., . . . Hober, S. (2020). High throughput generation of a resource of the human secretome in mammalian cells. New Biotechnology, 58, 45-54
Open this publication in new window or tab >>High throughput generation of a resource of the human secretome in mammalian cells
Show others...
2020 (English)In: New Biotechnology, ISSN 1871-6784, E-ISSN 1876-4347, Vol. 58, p. 45-54Article in journal (Refereed) Published
Abstract [en]

The proteins secreted by human tissues and blood cells, the secretome, are important both for the basic understanding of human biology and for identification of potential targets for future diagnosis and therapy. Here, a high-throughput mammalian cell factory is presented that was established to create a resource of recombinant full-length proteins covering the majority of those annotated as 'secreted' in humans. The full-length DNA sequences of each of the predicted secreted proteins were generated by gene synthesis, the constructs were transfected into Chinese hamster ovary (CHO) cells and the recombinant proteins were produced, purified and analyzed. Almost 1,300 proteins were successfully generated and proteins predicted to be secreted into the blood were produced with a success rate of 65%, while the success rates for the other categories of secreted proteins were somewhat lower giving an overall one-pass success rate of ca. 58%. The proteins were used to generate targeted proteomics assays and several of the proteins were shown to be active in a phenotypic assay involving pancreatic beta-cell dedifferentiation. Many of the proteins that failed during production in CHO cells could be rescued in human embryonic kidney (HEK 293) cells suggesting that a cell factory of human origin can be an attractive alternative for production in mammalian cells. In conclusion, a high-throughput protein production and purification system has been successfully established to create a unique resource of the human secretome.

Place, publisher, year, edition, pages
Elsevier BV, 2020
Keywords
secreted proteins, protein production, protein puri fication, high-throughput
National Category
Cell and Molecular Biology
Identifiers
urn:nbn:se:kth:diva-278779 (URN)10.1016/j.nbt.2020.05.002 (DOI)000546033400007 ()32502629 (PubMedID)2-s2.0-85086565278 (Scopus ID)
Note

QC 20200729

Available from: 2020-07-29 Created: 2020-07-29 Last updated: 2023-12-07Bibliographically approved
Abdellah, T., Gummesson, A., Zhong, W., Koistinen, I. S., Lakshmikanth, T., Olsson, L. M., . . . Fagerberg, L. (2020). Integration of molecular profiles in a longitudinal wellness profiling cohort. Nature Communications, 11(1), Article ID 4487.
Open this publication in new window or tab >>Integration of molecular profiles in a longitudinal wellness profiling cohort
Show others...
2020 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 11, no 1, article id 4487Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Nature Publishing Group, 2020
Keywords
General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry
National Category
Bioinformatics and Computational Biology
Research subject
Biotechnology
Identifiers
urn:nbn:se:kth:diva-303344 (URN)10.1038/s41467-020-18148-7 (DOI)000607103200020 ()32900998 (PubMedID)2-s2.0-85090387884 (Scopus ID)
Note

QC 20211110

Available from: 2021-10-12 Created: 2021-10-12 Last updated: 2025-02-07Bibliographically approved
Kotol, D., Hunt, H., Hober, A., Karlsson, M. J., Forsström, B., Gummesson, A., . . . Edfors, F. (2020). Longitudinal Plasma Protein Profiling Using Targeted Proteomics and Recombinant Protein Standards. Journal of Proteome Research, 19(12), 4815-4825
Open this publication in new window or tab >>Longitudinal Plasma Protein Profiling Using Targeted Proteomics and Recombinant Protein Standards
Show others...
2020 (English)In: Journal of Proteome Research, ISSN 1535-3893, E-ISSN 1535-3907, Vol. 19, no 12, p. 4815-4825Article in journal (Refereed) Published
Abstract [en]

Spike-in of standards of known concentrations used in proteomics-based workflows is an attractive approach for both accurate and precise multiplexed protein quantification. Here, a quantitative method based on targeted proteomics analysis of plasma proteins using isotope-labeled recombinant standards originating from the Human Protein Atlas project has been established. The standards were individually quantified prior to being employed in the final multiplex assay. The assays are mainly directed toward actively secreted proteins produced in the liver, but may also originate from other parts of the human body. This study included 21 proteins classified by the FDA as either drug targets or approved clinical protein biomarkers. We describe the use of this multiplex assay for profiling a well-defined human cohort with sample collection spanning over a one-year period. Samples were collected at four different time points, which allowed for a longitudinal analysis to assess the variable plasma proteome within individuals. Two assays toward APOA1 and APOB had available clinical data, and the two assays were benchmarked against each other. The clinical assay is based on antibodies and shows high correlation between the two orthogonal methods, suggesting that targeted proteomics with highly parallel, multiplex analysis is an attractive alternative to antibody-based protein assays.

Place, publisher, year, edition, pages
American Chemical Society (ACS), 2020
Keywords
mass spectrometry, proteomics, blood plasma, stable isotope standards, absolute quantification, recombinant protein standards, precision medicine
National Category
Biochemistry Molecular Biology
Identifiers
urn:nbn:se:kth:diva-289041 (URN)10.1021/acs.jproteome.0c00194 (DOI)000598145200009 ()32820635 (PubMedID)2-s2.0-85097211012 (Scopus ID)
Note

QC 20210203

Available from: 2021-02-03 Created: 2021-02-03 Last updated: 2025-02-20Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-5248-8568

Search in DiVA

Show all publications